Isunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.
Alcaftadine ophthalmic solution 0.25% was superior to olopatadine hydrochloride ophthalmic solution 0.2% in reducing the itching related to grass and tree pollens in a multicenter, randomized study in subjects with allergic conjunctivitis.
As technology leaps forward with medicine, it is prudent at times to appreciate how far we have come in managing and treating allergic eye disease. In fact, let us look back to the beginning in ancient Rome with the first recorded case of atopy. One of these authors, Suetonius, wrote with great detail in his biographical text De vita Caeserum about the distinctive lives of the first Roman emperors.
As optometry’s scope of practice has increased, optometrists have embraced allergic eye disease. Ocular allergies have multiple effects to patients in our practice. But, if allergies are unidentified because symptoms may not be present during office visits, patients may treat themselves.
A new, first-in-class, aldehyde-trap topical drop demonstrated rapid onset of action and sustained efficacy with an acceptable safety profile in a phase II clinical trial of patients with moderate-to-severe allergic conjunctivitis.
The arrival of spring also signals the onset of ocular allergy season. Clinicians can prepare by knowing and recognizing the symptoms in their patients, as well as being informed about the latest therapies for this diagnosis.
If you think more allergy patients are landing in your chair every year, you’re absolutely correct. The prevalence of allergy is rising worldwide to near epidemic proportions and carries a significant burden for both the individual patient as well as healthcare systems globally.